吡柔比星与米托蒽醌治疗慢性粒细胞白血病急性变的疗效比较  

Comparison of Efficacy of Pirarubicin and Mitoxantrone in Treatment of Patients with Chronic Myeloid Leukemia in Blast Crisis

作　　者：韩坤元[1] 王好问[1] 林到勇[1] 

机构地区：[1]海南省人民医院,海南海口570311

出　　处：《中国药业》2006年第18期57-58,共2页China Pharmaceuticals

摘　　要：目的探讨以吡柔比星或米托蒽醌为主的联合化疗治疗慢性粒细胞白血病(CML)急性变的疗效。方法对52例患者采用以吡柔比星或米托蒽醌为主的联合化疗治疗方案,疗程5～7d,根据血常规及骨髓检查结果决定用药时间。结果以吡柔比星或米托蒽醌为主的联合化疗的近期总有效率分别为41.4%和43.5%,临床感染率分别为34.2%和42.5%,两组比较均无统计学差异。结论以吡柔比星或米托蒽醌为主的联合化疗治疗CML急性变时,近期疗效肯定,但以米托蒽醌为主的联合化疗感染率较高。Objective To compare the efficacy of pirarubicin and mitoxantrone in the treatment of patients with chronic myeloid leukemia in blast crisis. Methods Fifty-two patients with chronic myeloid leukemia in blast crisis were treated by combined chemotherapy （including pirarubicin or mitoxantrone） for 5 -7 d according to the blood or bone marrow test. Results The total efficiency of THP group and MIT group are 41.4% and 43.5% ,respectively, The clinical infection rate were 34. 22% and 42.5% in THP group and MIT group. There are no statistical significance of difference between two groups （P 〉 0.05）. Conclusion The efficiency of two kinds of combined chemotherapy （including pirarubicin or mitoxantrone） in the treatment of chronic myeloid leukemia in blast crisis in recent time was affirmative,and the clinical infection rate was higher in MIT group.

关 键 词：慢性粒细胞白血病急性变 吡柔比星 米托蒽醌 联合化疗 疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]